» Articles » PMID: 35524669

Epilepsy and Alzheimer's Disease: Current Concepts and Treatment Perspective on Two Closely Related Pathologies

Overview
Date 2022 May 7
PMID 35524669
Authors
Affiliations
Soon will be listed here.
Abstract

The literature on epileptic seizures in Alzheimer's disease has significantly increased over the past decades. Remarkably, several studies suggest a bi-directional link between these two common neurological diseases, with either condition carrying a nearly 2-fold risk of contracting the other in comparison to healthy subjects. In this respect, evidence from both clinical and preclinical studies indicates that epileptogenesis and neurodegeneration possibly share common underlying mechanisms. However, the precise association between epileptogenesis and neurodegeneration still needs to be fully elucidated. Targeted intervention to reduce abnormal network hyperexcitability might constitute a therapeutic strategy to postpone the onset of later neurodegenerative changes and consequent cognitive decline by many years in patients. By virtue of this, an early diagnosis and treatment of seizures in patients with Alzheimer's disease should be pursued. To date, no guidelines are available for treating epileptic activity in this context, largely due to the paucity of studies sufficient to answer the related questions. Accordingly, clinical trials are mandatory, not only to inform clinicians about symptomatic management of seizures in Alzheimer's disease patients but also to detect if treatment with antiseizure medications could have disease-modifying effects. Moreover, it will be fundamental to expand the application of animal models of Alzheimer's disease to comorbid conditions, such as epilepsy both to reveal the mechanisms underlying seizure onset and to better define their role in cognitive decline. Such models could also be useful to identify pharmacological compounds having therapeutically effectiveness as well as reliable early biomarkers for seizures in Alzheimer's disease.

Citing Articles

Alzheimer's Disease and Epilepsy: Exploring Shared Pathways and Promising Biomarkers for Future Treatments.

Kalyvas A, Dimitriou M, Ioannidis P, Grigoriadis N, Afrantou T J Clin Med. 2024; 13(13).

PMID: 38999445 PMC: 11242231. DOI: 10.3390/jcm13133879.


Investigating the causal relationship between immune cell and Alzheimer's disease: a mendelian randomization analysis.

Shen M, Zhang L, Chen C, Wei X, Ma Y, Ma Y BMC Neurol. 2024; 24(1):98.

PMID: 38500057 PMC: 10946133. DOI: 10.1186/s12883-024-03599-y.


Antiseizure Medications in Alzheimer's Disease from Preclinical to Clinical Evidence.

Bosco F, Guarnieri L, Rania V, Palma E, Citraro R, Corasaniti M Int J Mol Sci. 2023; 24(16).

PMID: 37628821 PMC: 10454935. DOI: 10.3390/ijms241612639.

References
1.
. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1250-1284. PMC: 7562819. DOI: 10.1016/S0140-6736(20)30750-9. View

2.
Born H . Seizures in Alzheimer's disease. Neuroscience. 2014; 286:251-63. DOI: 10.1016/j.neuroscience.2014.11.051. View

3.
Kanner A, Helmstaedter C, Sadat-Hossieny Z, Meador K . Cognitive disorders in epilepsy I: Clinical experience, real-world evidence and recommendations. Seizure. 2020; 83:216-222. DOI: 10.1016/j.seizure.2020.10.009. View

4.
Palop J, Mucke L . Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol. 2009; 66(4):435-40. PMC: 2812914. DOI: 10.1001/archneurol.2009.15. View

5.
Profenno L, Jakimovich L, Holt C, Porsteinsson A, Tariot P . A randomized, double-blind, placebo-controlled pilot trial of safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease. Curr Alzheimer Res. 2005; 2(5):553-8. DOI: 10.2174/156720505774932205. View